During the corresponding time, Delcath Systems Inc recorded a revenue increase by 20.6 % year on year, sequentially revenue grew by 20.1 %. While revenue at the Delcath Systems Inc 's corporate clients
Delcath Systems Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal health programs and private third-party payors. Its market includes manufacturers of drugs, devices, biologicals, and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program. Key segments comprise physicians (doctors, dentists, optometrists, podiatrists, chiropractors), other healthcare professionals (physician assistants, nurse practitioners), teaching hospitals, and pharmaceutical sales representatives. Additionally, the company engages with covered entities such as healthcare providers, health plans, healthcare clearinghouses, and their business associates that handle individually identifiable health information in compliance with HIPAA and HITECH regulations.
Targeting Liver Tumors: Delcath Systems Promising Developments in Oncology Delcath Systems, Inc., a leader in the field of interventional oncology, has made significant strides in the ongoing battle against primary and metastatic liver cancers. As the 2025 European Society for Medical Oncology (ESMO) Congress unfolds, Delcath s recent achievements underline the company s pivotal role in advancing treatment options and improving patient outcomes. Pioneering Trials at ESMO 2025 Congress One of the highlights of Delcath s advancements is the acceptance of an oral presentation on the CHOPIN randomized Phase 2 trial. Led by Principal Investigator Dr. Ellen Kapiteijn from Leiden University Medical Center, this in...
In a significant move aimed at bolstering its growth and operational capabilities, Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering interventional oncology company focused on innovative treatments for primary and metastatic cancers of the liver, has announced the grant of equity awards as inducements to new hires. This decision reflects the company s ongoing commitment to enhancing its workforce and advancing its mission in the fight against liver cancer.The press release, issued from the company’s headquarters in Queensbury, New York, outlines that these inducement grants were approved by Delcath s Compensation Committee and are part of the company s strategic approach to attract top talent in the oncol...
QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH) continues to demonstrate its commitment to fostering industry-leading talent as part of its broader strategy ...
QUEENSBURY, N.Y. In an assertive move to bolster its talented roster, Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company dedicated to the treatment of primary and metastatic cancers of the liver, disclosed the issuance of three distinct equity awards to new employees as part of its strategic growth plan. These inducement grants, sanctioned by the Company s Compensation Committee, were awarded to attract and retain high-caliber individuals whose roles commenced in August 2024. Delcath, specializing in innovative therapeutics designed to treat hepatic malignancies, recognizes that the foundation of its groundbreaking work is deeply rooted in the expertise and dedication of its wo...
Promising New Data from Delcath Systems Highlights Efficacy of HEPZATO KIT in Treating Metastatic Uveal Melanoma SubgroupsIn a significant development for the oncology community, Delcath Systems, Inc. (Nasdaq: DCTH), an innovative company specializing in liver-directed cancer therapies, unveiled compelling new data at the European Society for Medical Oncology (ESMO) Congress 2024. The data, presented by Dr. Matthew Wheater from University Hospital Southampton, builds a strong case for the efficacy of their groundbreaking treatment, HEPZATO KIT (melphalan/Hepatic Delivery System (HDS)), in specific subgroups of patients affected by metastatic uveal melanoma (mUM). A Deep Dive into Metastatic Uveal MelanomaUv...
In the ever-evolving landscape of cancer treatment, few companies are making as significant an impact as Delcath Systems, Inc. (Nasdaq: DCTH). Based in Queensbury, New York, Delcath has emerged as a leading player in interventional oncology, particularly focused on treating primary and metastatic liver cancers. With recent promising results from independent studies and noteworthy financial performance, the company is poised for continued growth and innovation. Promising Results from Independent StudyDelcath s recent announcement of promising results from an independent study has intensified interest in its Hepatic Chemo Saturation (HCS) therapy. Conducted by a team of researchers at the University Hospital o...
Delcath Systems Inc., a New York-based interventional oncology company dedicate...
Delcath Systems Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal health programs and private third-party payors. Its market includes manufacturers of drugs, devices, biologicals, and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program. Key segments comprise physicians (doctors, dentists, optometrists, podiatrists, chiropractors), other healthcare professionals (physician assistants, nurse practitioners), teaching hospitals, and pharmaceutical sales representatives. Additionally, the company engages with covered entities such as healthcare providers, health plans, healthcare clearinghouses, and their business associates that handle individually identifiable health information in compliance with HIPAA and HITECH regulations.
Sources:
Delcath Systems Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Delcath Systems Inc’s corporate clients.
For your research, we’ve provided 9 tables on Delcath Systems Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
12.77 %